$1.46 billion!

On August 8, Mersana Therapeutics, a clinical-stage biopharmaceutical company in the United States, announced an agreement with GSK on the co-development and commercialization of XMT-2056, an Immunosynthen ADC targeting a HER2 neo-epitope.

Massachusetts-based Mersana is focused on developing ADCs for cancer, leveraging its differentiated and proprietary ADC platform to rapidly develop novel ADCs with optimal efficacy, safety and tolerability

Many different factors affect ADC properties, including payload, drug-to-antibody ratio, binding site, and homogeneity

Mersana's technology platform (Source: Mersana official website)

Mersana's lead product candidate, upifitamab rilsodotin (UpRi), a dolaflexin ADC targeting NaPi2b, is currently under development in UPLIFT (a single-arm registration trial in patients with platinum-resistant ovarian cancer) and UPGRADE (evaluating UpRi with other ovarian cancer therapies) combined use of the Phase I/II umbrella study clinical trial)

Mersana's earlier projects include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056

Mersana's R&D pipeline (source: Mersana official website)

XMT-2056 activates the innate immune system through STING signaling in tumor-resident immune cells and tumor cells

Mersana expects to initiate a Phase I clinical trial of XMT-2056 to investigate its potential in a range of HER2-expressing tumors including breast, gastric and non-small cell lung cancer

"GSK brings highly complementary development and commercial capabilities, extensive immuno-oncology experience, a deep understanding of the STING pathway, and a shared vision to unlock the broad potential of XMT-2056," said Anna Protopapas, President and CEO of Mersana

John Lepore, senior vice president of research at GSK, said: "GSK's goal is to bring transformative treatment options to cancer patients, so we are delighted to have entered into this agreement for XMT-2056

Original in English: https://ir.